Here's some cool new research coming from The University of North Carolina School of Medicine, a formulation designed to increase the bioavailability of a drug used to treat Tuberculosis. According to Miriam Braunstein, PhD, "During the COVID-19 pandemic, we witnessed more deaths due to TB because of disruption or reallocation of health services, setting us back at least five to eight years in the global fight against TB. We think long-acting formulations could be a game-changer, whether it’s for preventative therapy or treatment of disease.” Read more here.
top of page
bottom of page